The AZALEA–TIMI 71 trial compared abelacimab, a monoclonal antibody targeting factor XI, with rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk.

🚨 New study: Abelacimab vs. Rivaroxaban in AFib 📊

✅ 62-69% lower bleeding risk than rivaroxaban ✅ 5x lower GI bleeding ⚠️ Slightly higher ischemic stroke rates

A promising safer anticoagulant? 🔬 More data needed! #CardioTwitter #CardioEd #MedEd

Abelacimab significantly reduced bleeding compared to rivaroxaban (HR: 0.38 for 150 mg, 0.31 for 90 mg, p